loading page

The Janus face of Ouabain in Na+, K+-ATPase and calcium signalling in neurons
  • +4
  • Paula Kinoshita,
  • Ana Orellana,
  • Vinicius Nakao,
  • Natacha de Souza Port´s,
  • Luis Quintas,
  • Elisa Kawamoto,
  • Cristoforo Scavone (GUEST EDITOR)
Paula Kinoshita
Universidade de São Paulo

Corresponding Author:[email protected]

Author Profile
Ana Orellana
Universidade de Sao Paulo
Author Profile
Vinicius Nakao
Universidade de São Paulo
Author Profile
Natacha de Souza Port´s
Universidade de São Paulo
Author Profile
Luis Quintas
Universidade Federal do Rio de Janeiro
Author Profile
Elisa Kawamoto
Universidade de São Paulo
Author Profile
Cristoforo Scavone (GUEST EDITOR)
Universidade de São Paulo
Author Profile


Na+,K+ATPase (NKA), a transmembrane protein essential for maintaining the electrochemical gradient across the plasma membrane, acts as a receptor for cardiotonic steroids (CTS) such as ouabain. CTS binding to NKA, triggers signalling pathways or inhibits NKA activity in a concentration-dependent manner, resulting in a modulation of Ca2+ levels, which are essential for homeostasis in neurons. However, most of the pharmacological strategies for avoiding neuronal death do not target NKA activity, due to its complexity and poor comprehension of the mechanisms involved in NKA modulation. The present review aims to discuss two points regarding the interplay between NKA and Ca2+ signalling in the brain: NKA impairment causing illness as well as neuronal death due to Ca2+ signalling and benefits to the brain by modulating NKA activity. These interactions play an essential role in neuronal cell fate determination and are relevant to finding new targets for the treatment of neurodegenerative diseases.
09 Dec 2020Submitted to British Journal of Pharmacology
10 Dec 2020Submission Checks Completed
10 Dec 2020Assigned to Editor
10 Dec 2020Reviewer(s) Assigned
04 Jan 2021Review(s) Completed, Editorial Evaluation Pending
06 Jan 2021Editorial Decision: Revise Minor
01 Feb 20211st Revision Received
03 Feb 2021Submission Checks Completed
03 Feb 2021Assigned to Editor
04 Feb 2021Reviewer(s) Assigned
11 Feb 2021Review(s) Completed, Editorial Evaluation Pending
14 Feb 2021Editorial Decision: Accept
Apr 2022Published in British Journal of Pharmacology volume 179 issue 8 on pages 1512-1524. 10.1111/bph.15419